Emergent BioSolutions Secures $18M CAD Order for NARCAN® Nasal Spray in British Columbia — Emergent BioSolutions Inc.

Event summary

Emergent BioSolutions has partnered with the B.C. Provincial Health Services Authority to supply NARCAN® Nasal Spray for the expanded BC Take Home Naloxone Program.
The B.C. government invested an additional $18 million CAD to expand the program, which will now include nasal naloxone.
This expansion follows a successful pilot program in 2024 that distributed 60,000 nasal naloxone kits across various community sites.
Emergent has delivered over 100 million doses of NARCAN® Nasal Spray in Canada and the U.S. since 2016.

The big picture

This partnership underscores the growing emphasis on nasal naloxone as a critical tool in combating the opioid crisis. The $18 million CAD investment highlights the strategic importance of expanding access to opioid reversal therapies, particularly in regions heavily impacted by opioid-related overdoses. Emergent's longstanding role in supplying NARCAN® Nasal Spray positions it as a key player in the public health response to this crisis.

What we're watching

Market Expansion: How the success of this program will influence similar initiatives in other provinces or regions.
Regulatory Dynamics: Whether the increased investment in nasal naloxone will lead to broader regulatory support for opioid reversal therapies.
Execution Risk: The pace at which Emergent can scale production to meet growing demand for NARCAN® Nasal Spray.